These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 34069373)
1. Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells. Son Y; Shin NR; Kim SH; Park SC; Lee HJ Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069373 [TBL] [Abstract][Full Text] [Related]
2. RABL2A-CCDC34 Axis Promotes Sorafenib Resistance in Hepatocellular Carcinoma. Zhou M; Chen X; Bai H; Sun Y; Zhang Z; Li S; Wang X; Zeng M DNA Cell Biol; 2021 Nov; 40(11):1418-1427. PubMed ID: 34767735 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma. Liu D; Fan Y; Li J; Cheng B; Lin W; Li X; Du J; Ling C Oncol Rep; 2018 Oct; 40(4):2206-2214. PubMed ID: 30066934 [TBL] [Abstract][Full Text] [Related]
4. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046 [TBL] [Abstract][Full Text] [Related]
5. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro. Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356 [TBL] [Abstract][Full Text] [Related]
6. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines. Kim JS; Choi GH; Jung Y; Kim KM; Jang SJ; Yu ES; Lee HC J Cancer Res Clin Oncol; 2018 Aug; 144(8):1487-1501. PubMed ID: 29858683 [TBL] [Abstract][Full Text] [Related]
7. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma. Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295 [TBL] [Abstract][Full Text] [Related]
8. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043 [TBL] [Abstract][Full Text] [Related]
9. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma. Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343 [TBL] [Abstract][Full Text] [Related]
10. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. Firtina Karagonlar Z; Koc D; Iscan E; Erdal E; Atabey N Cancer Sci; 2016 Apr; 107(4):407-16. PubMed ID: 26790028 [TBL] [Abstract][Full Text] [Related]
11. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma. Deng L; Sun J; Chen X; Liu L; Wu D J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849 [TBL] [Abstract][Full Text] [Related]
12. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma. Wu J; Chai H; Li F; Ren Q; Gu Y Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976 [TBL] [Abstract][Full Text] [Related]
13. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740 [TBL] [Abstract][Full Text] [Related]
14. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells. Gao L; Morine Y; Yamada S; Saito Y; Ikemoto T; Tokuda K; Takasu C; Miyazaki K; Shimada M PLoS One; 2021; 16(9):e0256755. PubMed ID: 34473785 [TBL] [Abstract][Full Text] [Related]
15. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. Tomonari T; Takeishi S; Taniguchi T; Tanaka T; Tanaka H; Fujimoto S; Kimura T; Okamoto K; Miyamoto H; Muguruma N; Takayama T Oncotarget; 2016 Feb; 7(6):7207-15. PubMed ID: 26769852 [TBL] [Abstract][Full Text] [Related]
16. miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression. Azumi J; Tsubota T; Sakabe T; Shiota G Cancer Sci; 2016 Sep; 107(9):1256-62. PubMed ID: 27384977 [TBL] [Abstract][Full Text] [Related]
17. MiR-375 attenuates sorafenib resistance of hepatocellular carcinoma cells by inhibiting cell autophagy. Wang D; Yang J Acta Biochim Pol; 2023 Apr; 70(2):239-246. PubMed ID: 37068178 [TBL] [Abstract][Full Text] [Related]
18. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells. Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812 [TBL] [Abstract][Full Text] [Related]
20. The correlation of fibrinogen-like protein-1 expression with the progression and prognosis of hepatocellular carcinoma. Hua N; Chen A; Yang C; Dong H; He X; Ru G; Tong X; Zhou F; Wang S Mol Biol Rep; 2022 Aug; 49(8):7911-7919. PubMed ID: 35776395 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]